| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net (loss) income | -4,760 | - |
| Depreciation and amortization | 1,646 | 1,102 |
| Stock-based compensation | 1,359 | 827 |
| Write-off of inventory | 178 | 178 |
| Change in inventory reserves | -61 | - |
| Non-cash lease expense from right of use assets | 1,616 | 1,091 |
| Amortization of debt financing costs and accretion of debt discount and premium | 265 | 176 |
| Loss on disposal of assets | -56 | -57 |
| Realized gain on sale of investments | 181 | - |
| Gain on rou early terminations | 24 | - |
| Accounts receivable | 37 | -207 |
| Inventory | -1,875 | -1,618 |
| Prepaid and other assets | -470 | -1,043 |
| Accounts payable | -1,344 | -1,367 |
| Lease liabilities | -1,229 | -808 |
| Accrued and other liabilities | -2,304 | -2,165 |
| Deferred license revenue | -475 | -475 |
| Net cash (used in) provided by operating activities | -2,950 | -1,643 |
| Purchases of investments available-for-sale | 12,957 | 5,877 |
| Proceeds from sales of investments available-for-sale | 9,000 | 6,000 |
| Purchases of equipment | 456 | 227 |
| Net cash used in investing activities | -4,413 | -104 |
| Payments on insurance financing note payable | 466 | 268 |
| Payments on financing lease liabilities | 418 | 294 |
| Proceeds from issuance of common stock | 7,816 | 0 |
| Deferred consideration paid in connection with evoqua asset acquisition | 1,621 | 871 |
| Net cash provided by financing activities | 5,311 | -1,433 |
| Effect of exchange rate changes on cash and cash equivalents | 0 | 0 |
| Net (decrease) increase in cash and cash equivalents | -2,052 | -3,180 |
| Cash and cash equivalents at beginning of period | 15,662 | - |
| Cash and cash equivalents at end of period | 13,610 | - |
ROCKWELL MEDICAL, INC. (RMTI)
ROCKWELL MEDICAL, INC. (RMTI)